Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 9

1.

Carboplatin and oxaliplatin in sequenced combination with bortezomib in ovarian tumour models.

Al-Eisawi Z, Beale P, Chan C, Yu JQ, Huq F.

J Ovarian Res. 2013 Nov 9;6(1):78. doi: 10.1186/1757-2215-6-78.

PMID:
24209693
[PubMed]
Free PMC Article
2.

Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.

Chen Z, Pittman EF, Romaguera J, Fayad L, Wang M, Neelapu SS, McLaughlin P, Kwak L, McCarty N.

PLoS One. 2013 Aug 2;8(8):e69126. doi: 10.1371/journal.pone.0069126. Print 2013.

PMID:
23936317
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.

Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG.

Mol Cancer Ther. 2013 Jun;12(6):1140-50. doi: 10.1158/1535-7163.MCT-12-1151. Epub 2013 Mar 27.

PMID:
23536725
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.

Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S.

Br J Haematol. 2013 Apr;161(1):43-56. doi: 10.1111/bjh.12206. Epub 2013 Jan 30.

PMID:
23360303
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Targeting malignant B cells with an immunotoxin against ROR1.

Baskar S, Wiestner A, Wilson WH, Pastan I, Rader C.

MAbs. 2012 May-Jun;4(3):349-61. doi: 10.4161/mabs.19870. Epub 2012 Apr 26.

PMID:
22531447
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.

Dasmahapatra G, Lembersky D, Son MP, Patel H, Peterson D, Attkisson E, Fisher RI, Friedberg JW, Dent P, Grant S.

Mol Cancer Ther. 2012 May;11(5):1122-32. doi: 10.1158/1535-7163.MCT-12-0021. Epub 2012 Mar 12.

PMID:
22411899
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.

Chapman CM, Sun X, Roschewski M, Aue G, Farooqui M, Stennett L, Gibellini F, Arthur D, Pérez-Galán P, Wiestner A.

Clin Cancer Res. 2012 Apr 1;18(7):1979-91. doi: 10.1158/1078-0432.CCR-11-2113. Epub 2012 Feb 20.

PMID:
22351695
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities.

Jung HJ, Chen Z, Wang M, Fayad L, Romaguera J, Kwak LW, McCarty N.

Blood. 2012 Mar 15;119(11):2568-78. doi: 10.1182/blood-2011-09-377598. Epub 2012 Jan 31.

PMID:
22294726
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

New molecular targets in mantle cell lymphoma.

Parekh S, Weniger MA, Wiestner A.

Semin Cancer Biol. 2011 Nov;21(5):335-46. doi: 10.1016/j.semcancer.2011.09.008. Epub 2011 Sep 18. Review.

PMID:
21945517
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk